Finally, families may play an even greater role in providing care and support to children, adolescents and young adults with schizophrenia CHES compared to adults. Given the robust evidence for the efficacy of family interventions in adult schizophrenia, these interventions may be particularly promising in children, adolescents and young adults. A previous review of antipsychotic medications for childhood-onset schizophrenia found limited evidence regarding the effectiveness of antipsychotic medication in this population, but searches were conducted in 2007 and the review did not include participants over the age of 13 years. The evidence indicates there are few advantages of second-generation antipsychotics over first-generation antipsychotics in treating psychosis, suggesting they could be combined in a meta-analysis. Research in this field has advanced rapidly in recent years, and a current review is needed to determine the efficacy and safety of pharmacological, psychological and combination interventions in the treatment of children, adolescents and young adults with AZ 12216052 Psychosis and schizophrenia. Subgroup analyses were conducted for different doses of antipsychotic medication, where more than one dose was compared with placebo. We used the lower and upper dose ranges identified by the Prescribing Observatory for Mental Health, United Kingdom Topic 10 benchmarking exercise of antipsychotic prescribing in children and young people in practice, to categorise doses administered in the included trials as either ��lower�� or ��higher�� doses of medication. Therefore, ��higher�� doses are those exceeding the maximum dose stated in the manufacturers�� summary of product characteristics for that drug, and ��lower�� doses are those under the minimum dose stated in the manufacturers�� summary of product characteristics for that drug. Because children, adolescents and young adults previously unexposed to antipsychotics may be particularly vulnerable to weight gain associated with antipsychotic use, we also conducted subgroup analyses for FEP and subsequent acute episode groups. FEP and subsequent acute episode groups were defined as reported by the trial authors. Psychosis and schizophrenia in children, adolescents and young adults are very serious and debilitating illnesses, which in clinical practice usually leads to the use of antipsychotics. However, in the absence of high quality evidence for the effectiveness of antipsychotic medication in children, adolescents and young adults, their routine use in the treatment of psychosis and schizophrenia should be undertaken cautiously.